Latest news with #Rameda
Zawya
14-05-2025
- Business
- Zawya
Egypt: Rameda reports 44.3% YoY consolidated profit decline in Q1 2025
Arab Finance: The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) posted a 44.26% year-on-year (YoY) leap in consolidated net profits attributable to the parent company in the first quarter (Q1) of 2025, achieving EGP 82.243 million from EGP 57.009 million, according to a statement. However, revenues jumped to EGP 865.616 million in the January-March period, up from EGP 456.233 million in the corresponding period a year ago. Rameda's standalone net profits after tax rose to EGP 76.717 million in Q1 2025 from EGP 53.539 million in Q1 2024. Rameda is an Egypt-based pharmaceutical company that manufactures both human and veterinary pharmaceuticals. It operates three fully independent factories at its plant, including 20 production lines capable of producing a wide range of general medicinal forms, namely eye drops, solid dosage forms, syrups, blow-fill-seal, and lyophilized vials, among others. © 2020-2023 Arab Finance For Information Technology. All Rights Reserved. Provided by SyndiGate Media Inc. (
Zawya
30-04-2025
- Business
- Zawya
Egypt: Rameda to pay $3.15mln cash dividends for 2024
The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents' (Rameda) ordinary general meeting (OGM) approved the distribution of cash dividends valued at EGP 160 million for 2024 to shareholders over two equal installments, according to a bourse filing. The first payment will be in June 2025, while the second instalment will be in November 2025. The OGM also endorsed the distribution of bonus shares worth EGP 122.25 million, equivalent to 0.3236:1 share. Rameda posted a 58.2% year-on-year (YoY) uptick in consolidated profits attributable to the parent company in 2024 to EGP 387.366 million, versus EGP 244.859 million. © 2020-2023 Arab Finance For Information Technology. All Rights Reserved. Provided by SyndiGate Media Inc. (
Zawya
11-03-2025
- Business
- Zawya
Egypt: Rameda's consolidated profits up 58.2% YoY in 2024
Arab Finance: The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) posted a 58.2% year-on-year (YoY) uptick in consolidated profits attributable to the parent company in 2024 to EGP 387.366 million versus EGP 244.859 million, a statement showed. However, revenues jumped to EGP 2.768 billion last year from EGP 1.922 billion in the prior year. Rameda's standalone net profits after tax slipped to EGP 373.237 million in 2024, compared to EGP 234.455 million in 2023. Rameda is an Egypt-based pharmaceutical company that manufactures both human and veterinary pharmaceuticals. It operates three fully independent factories at its plant, including 20 production lines capable of producing a wide range of general medicinal forms, namely eye drops, solid dosage forms, syrups, blow-fill-seal, and lyophilized vials, among others. © 2020-2023 Arab Finance For Information Technology. All Rights Reserved. Provided by SyndiGate Media Inc. (
